Speeding up the development of and access to innovative medical countermeasures: point-of-care metagenomic sequencing for universal pathogen detection

This tender calls for the development of a test based on metagenomic next-generation sequencing (mNGS) that can detect any respiratory/airborne viral pathogen, including novel and emerging pathogens, from any human respiratory sample type.

The scope of the call for tenders focuses on: 

1. Speeding up the development of promising diagnostics that are meant to diagnose/detect, prevent, protect from, or treat conditions associated to serious cross-border health threats; 
2. The acquisition of the priority right to purchase to ensure access to the investigational medicinal products (IMPs) and products. 

Estimated ceiling: €24 000 000

Read more and apply on the Funding and Tenders Portal.

Background

EU4Health is the fourth and largest of the EU health programmes. The EU4Health programme goes beyond an ambitious response to the COVID-19 crisis to address the resilience of European healthcare systems. The programme provides funding to national authorities, health organisations and other bodies through grants and public procurement, contributing to a healthier Europe.

HaDEA manages the vast majority of the total EU4Health budget and implements the programme by managing calls for proposals and tenders from 2021 to 2027.

This action supports the EU4Health policy priority to be better prepared to respond to cross-border health threats. It contributes to the achievement of the EU4Health programme’s general objective of protecting people in the Union from serious cross-border threats to health and strengthening the responsiveness of health systems and coordination among EU countries to cope with serious cross-border threats to health (Article 3, point (b) of Regulation (EU) 2021/522) through the specific objectives defined in Article 4, points (b) and (c), of Regulation (EU) 2021/522.